Oncology Today with Dr Neil Love

Featuring an interview with Prof Karim Fizazi, including the following topics:
Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
Role of intermittent therapy in the treatment of prostate cancer (38:48)
Treatment intensification approaches in prostate cancer (41:38)
Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:
Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00)
Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58)
Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:
Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
Mechanism of action of avutometinib/defactinib (10:16)
RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)
Ongoing clinical trials in low-grade serous ovarian cancer (27:57)

CME information and select publications

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications

Featuring a slide presentation from Dr Julia Rotow, including the following topics:
Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)
Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)
Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)
Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)
Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)
Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

CME information and select publications